HK1195793A1 - 結合藥物組合物及其用途 - Google Patents
結合藥物組合物及其用途Info
- Publication number
- HK1195793A1 HK1195793A1 HK14109188.7A HK14109188A HK1195793A1 HK 1195793 A1 HK1195793 A1 HK 1195793A1 HK 14109188 A HK14109188 A HK 14109188A HK 1195793 A1 HK1195793 A1 HK 1195793A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical compositions
- combination pharmaceutical
- combination
- compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482568P | 2011-05-04 | 2011-05-04 | |
| PCT/US2012/036688 WO2012151562A1 (en) | 2011-05-04 | 2012-05-04 | Combination pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1195793A1 true HK1195793A1 (zh) | 2014-11-21 |
Family
ID=47108075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14109188.7A HK1195793A1 (zh) | 2011-05-04 | 2014-09-11 | 結合藥物組合物及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20140357651A1 (zh) |
| EP (1) | EP2705181B1 (zh) |
| JP (1) | JP6047149B2 (zh) |
| CN (1) | CN103703174B (zh) |
| CA (1) | CA2836769C (zh) |
| ES (1) | ES2618489T3 (zh) |
| HK (1) | HK1195793A1 (zh) |
| WO (1) | WO2012151562A1 (zh) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| CA2836769C (en) | 2011-05-04 | 2018-11-13 | Intellikine, Llc | The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder |
| JP6122420B2 (ja) * | 2011-05-06 | 2017-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 多発性嚢胞疾患の治療 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| WO2015002766A1 (en) * | 2013-07-02 | 2015-01-08 | Nikolai Khodarev | Anti-tumor therapy |
| JP6725501B2 (ja) | 2014-07-02 | 2020-07-22 | ザビエル・ユニバーシティ・オブ・ルイジアナＸａｖｉｅｒ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｌｏｕｉｓｉａｎａ | 少なくとも１つのフェノール（または芳香族ヒドロキシル）基を含有する薬物分子に関する増大された生物学的利用能及びより低い必要用量のためのホウ素系プロドラッグ戦略 |
| CN107073066B (zh) * | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| EP3209664B1 (en) | 2014-10-22 | 2020-06-03 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
| ES2749679T3 (es) | 2014-10-22 | 2020-03-23 | Bristol Myers Squibb Co | Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k |
| RS65129B1 (sr) | 2016-03-28 | 2024-02-29 | Incyte Corp | Jedinjenja pirolotriazina kao inhibitori tam |
| CA3020778A1 (en) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| PL3442535T3 (pl) | 2016-04-15 | 2022-10-24 | Cancer Research Technology Limited | Związki heterocykliczne jako inhibitory kinazy ret |
| CA3039582A1 (en) * | 2016-10-07 | 2018-04-12 | Abraxis Bioscience, Llc | Methods of treating biliary tract cancer |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| FR3075795A1 (fr) * | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| CN112368289B (zh) | 2018-05-01 | 2024-02-20 | 锐新医药公司 | 作为mtor抑制剂的c26-连接的雷帕霉素类似物 |
| RS64272B1 (sr) | 2018-05-01 | 2023-07-31 | Revolution Medicines Inc | C40-, c28- i c-32-vezani analozi rapamicina kao inhibitori mtor |
| WO2021157689A1 (ja) * | 2020-02-07 | 2021-08-12 | 範行 東 | 細胞周期のｇ１期初期制御剤 |
| US20230084515A1 (en) * | 2020-02-19 | 2023-03-16 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287105B6 (sk) * | 1999-12-20 | 2009-12-07 | Schering Corporation | Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním |
| JP2010532756A (ja) * | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法 |
| US8993580B2 (en) * | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| CA2730106A1 (en) * | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| JP5731978B2 (ja) * | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| CN102202668A (zh) * | 2008-10-31 | 2011-09-28 | 诺瓦提斯公司 | 磷脂酰肌醇-3-激酶(PI3K)抑制剂和mTOR抑制剂的组合产品 |
| US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| CA2836769C (en) | 2011-05-04 | 2018-11-13 | Intellikine, Llc | The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder |
-
2012
- 2012-05-04 CA CA2836769A patent/CA2836769C/en active Active
- 2012-05-04 EP EP12779459.2A patent/EP2705181B1/en active Active
- 2012-05-04 ES ES12779459.2T patent/ES2618489T3/es active Active
- 2012-05-04 WO PCT/US2012/036688 patent/WO2012151562A1/en active Application Filing
- 2012-05-04 US US14/113,982 patent/US20140357651A1/en not_active Abandoned
- 2012-05-04 JP JP2014509505A patent/JP6047149B2/ja active Active
- 2012-05-04 CN CN201280033418.1A patent/CN103703174B/zh active Active
-
2014
- 2014-09-11 HK HK14109188.7A patent/HK1195793A1/zh unknown
-
2016
- 2016-04-07 US US15/092,713 patent/US10172858B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2705181A1 (en) | 2014-03-12 |
| ES2618489T3 (es) | 2017-06-21 |
| EP2705181A4 (en) | 2014-10-08 |
| CN103703174A (zh) | 2014-04-02 |
| CA2836769A1 (en) | 2012-11-08 |
| WO2012151562A1 (en) | 2012-11-08 |
| US10172858B2 (en) | 2019-01-08 |
| JP6047149B2 (ja) | 2016-12-21 |
| CN103703174B (zh) | 2017-05-10 |
| CA2836769C (en) | 2018-11-13 |
| EP2705181B1 (en) | 2016-12-21 |
| JP2014513138A (ja) | 2014-05-29 |
| US20140357651A1 (en) | 2014-12-04 |
| US20160287595A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253870B (en) | Certain amino-pyrimidines and pharmaceutical preparations containing them | |
| HK1195793A1 (zh) | 結合藥物組合物及其用途 | |
| IL252566B (en) | Pharmacy preparations and methods | |
| ZA201300458B (en) | C-met-modulator pharmaceutical compositions | |
| GB201113662D0 (en) | Pharmaceutical compositions | |
| ZA201308208B (en) | Pharmaceutical compositions | |
| ZA201301766B (en) | Pharmaceutical compositions | |
| HK1199824A1 (zh) | 藥物組合物 | |
| ZA201207670B (en) | Pharmaceutical compositions | |
| ZA201300718B (en) | Pharmaceutical compositions | |
| EP2775831A4 (en) | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| SG10201508982TA (en) | Pharmaceutical compositions | |
| GB201118181D0 (en) | Pharmaceutical compositions | |
| GB201208315D0 (en) | Pharmaceutical methods and compositions | |
| EP2560678A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP2714715A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB201110598D0 (en) | Pharmaceutical compositions and devices | |
| GB201120470D0 (en) | Compositions and uses thereof | |
| IL226378A0 (en) | preparations@rokkhot | |
| GB201107454D0 (en) | Compositions and uses | |
| GB201101924D0 (en) | Compositions and uses | |
| AU2011900931A0 (en) | Pharmaceutical compositions and use thereof | |
| GB201008590D0 (en) | Pharmaceutical compositions |